Latest news with #AUPH
Yahoo
13-05-2025
- Business
- Yahoo
Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Total Revenue: $62.5 million, up 24% from $50.3 million in Q1 2024. Net Product Sales of LUPKYNIS: $60 million, up 25% from $48.1 million in Q1 2024. Cash Flow from Operations: $1.3 million, compared to negative $18.6 million in Q1 2024. Excluding restructuring payments, cash flow was $12.4 million. Cash, Cash Equivalents, and Investments: $312.9 million as of March 31, 2025, down from $358.5 million on December 30, 2024. Share Repurchase: 5.8 million shares repurchased for $47.4 million in Q1 2025. Cost of Revenue: $8.6 million, up from $7.8 million in Q1 2024. Gross Margin: 86%, compared to 85% in Q1 2024. Total Operating Expenses: $40.6 million, down from $63.6 million in Q1 2024. Net Income: $23.3 million or $0.17 per share, compared to a net loss of $10.7 million or $0.07 per share in Q1 2024. Warning! GuruFocus has detected 4 Warning Sign with DOLE. Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) reported a 24% increase in total revenue for Q1 2025, reaching $62.5 million compared to $50.3 million in Q1 2024. Net product sales of LUPKYNIS increased by 25% to $60 million in Q1 2025, driven by increased penetration in lupus nephritis treatment. The company generated positive cash flow from operations of $1.3 million in Q1 2025, a significant improvement from a negative cash flow of $18.6 million in Q1 2024. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a strong cash position with $312.9 million in cash, cash equivalents, restricted cash, and investments as of March 31, 2025. The company is on track to report initial results from the Phase 1 study of AUR200, a dual BAFF/APRIL inhibitor, later this quarter, indicating progress in their pipeline development. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) experienced a decrease in cash, cash equivalents, restricted cash, and investments from $358.5 million in December 2024 to $312.9 million in March 2025. The company repurchased 5.8 million of its common shares for $47.4 million, which could impact cash reserves. Total operating expenses were $40.6 million in Q1 2025, although reduced from $63.6 million in Q1 2024, still represent a significant cost. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) faces challenges from ANDA filers challenging the validity of its 2037 dosing protocol patent, posing potential future risks. The company is involved in ongoing patent litigation, which could lead to uncertainties and potential financial implications. Q: Can you discuss the quarterly sales cadence for LUPKYNIS and what's driving sales growth? A: Peter Greenleaf, President and CEO, explained that the sales growth is driven by a combination of new patient additions, persistency, and improved time to getting patients on the drug. The company is focusing on educating rheumatologists, which has shown positive results in prescribing trends. Historical patterns suggest a lift in sales towards the end of the year. Q: What are the expectations for the second quarter and the rest of the year based on historical trends? A: Peter Greenleaf noted that historically, the second and third quarters have been softer due to the summer, with a rise in the fourth quarter. The guidance range for the year is based on these historical trends, and the company is optimistic about maintaining growth. Q: How is Aurinia addressing the ANDA filers challenging the 2037 dosing protocol patent? A: Peter Greenleaf stated that Aurinia has filed patent infringement lawsuits against all ANDA filers and intends to vigorously defend its patents. The company is focused on ensuring the longevity of LUPKYNIS as a priority. Q: What is Aurinia's exposure to potential new federal government policies, such as tariffs and MFN legislation? A: Peter Greenleaf explained that the API for LUPKYNIS is manufactured in Switzerland, but several years' worth of product is stockpiled in the US, minimizing tariff impact. The company is monitoring potential changes in transfer pricing and government reimbursement policies closely. Q: Can you provide more details on the AUR200 Phase 1 study and its competitive positioning? A: Peter Greenleaf mentioned that the single ascending dose data for AUR200 will be reported by the end of June. The study will provide insights into pharmacokinetics and pharmacodynamics, which will help assess its competitive positioning against other APRIL/BAFF inhibitors. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Washington Post
12-05-2025
- Business
- Washington Post
Aurinia: Q1 Earnings Snapshot
EDMONTON, Alberta — EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (AUPH) on Monday reported first-quarter net income of $23.3 million, after reporting a loss in the same period a year earlier. The Edmonton, Alberta-based company said it had net income of 16 cents per share. The biotechnology company posted revenue of $62.5 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $60.9 million.
Yahoo
12-05-2025
- Business
- Yahoo
Aurinia: Q1 Earnings Snapshot
EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Monday reported first-quarter net income of $23.3 million, after reporting a loss in the same period a year earlier. The Edmonton, Alberta-based company said it had net income of 16 cents per share. The biotechnology company posted revenue of $62.5 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $60.9 million. Aurinia shares have fallen 11% since the beginning of the year. The stock has risen 59% in the last 12 months. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on AUPH at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
